Clinical Trial

Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this study is to learn about the safety, tolerability, immunogenicity and preliminary efficacy of BBM-C101 injection in patients with High-Grade Squamous Intraepithelial Lesion of the cervix. This study include two phases: Phase I and Phase IIa .
Trial Details
NCT Number NCT07668960
Lead Sponsor Shanghai Mianyi Biopharmaceutical Co., Ltd.
Conditions High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection
Enrollment 60 participants
Start Date 2026-06-17
Primary Completion 2029-12-30 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-25